Skip to main content

Table 4 Multivariable analyses of PFS and OS (Model 1)

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Variables

PFS

OS

HR

95% CI

p value

HR

95% CI

p value

Age (years)

  

0.443

  

0.973

  ≤ 65

Ref.

  

Ref.

  

 >65

1.177

0.776–1.787

 

0.992

0.634–1.553

 

ECOG PS

  

0.443

  

0.350

 0

Ref.

  

Ref.

  

 1

1.164

0.790–1.714

 

1.214

0.808–1.823

 

Clinical stage

  

0.003**

  

0.002**

 IIIB

Ref.

  

Ref.

  

 IV

1.807

1.229–2.658

 

1.880

1.260–2.806

 

First-line response

  

0.037*

  

0.011*

 CR/PR

Ref.

  

Ref.

  

 SD/PD

1.572

1.027–2.407

 

1.799

1.143–2.831

 

Albumin

  

0.089

   

 Decreased

1.377

0.952–1.991

    

 Normal

Ref.

     

LMR

  

0.025*

  

0.032*

  ≤ 3.73

1.602

1.060–2.420

 

1.621

1.042–2.521

 

 >3.73

Ref.

  

Ref.

  

SUVmax

  

< 0.001***

  

< 0.001***

  ≤ 11.6

Ref.

  

Ref.

  

 >11.6

2.110

1.400–3.179

 

2.760

1.789–4.257

 
  1. PFS progression-free survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, CR complete response, PR partial response, SD stable disease, PD progressive disease, LMR lymphocyte-monocyte ratio, SUVmax maximum standardized uptake value, HR hazard ratio, CI confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us